Health Catalyst price target raised to $15 from $9 at RBC Capital

RBC Capital analyst Sean Dodge raised the firm’s price target on Health Catalyst to $15 from $9 but keeps a Sector Perform rating on the shares after its smaller than expected Q4 earnings loss. The company’s lower revenue outlook is driven by weaker FY22 bookings and anticipated churn for slower-ROI solutions, though this is showing signs of recovery with a handful of recently announced client wins and expansions due in part to a heightened focus on cross-selling and up-selling, the analyst tells investors in a research note.